ZEISS Laser Vision Correction

Why rely on the global market leader in Laser Vision Correction? Innovative. Supportive. Trusted.

Go with decades of proven experience in laser vision correction.

Driven by pioneering innovation, global support and a trustworthy solutions, ZEISS offers one of the most comprehensive Laser Vision Correction portfolios in the industry, enabling tailored laser vision surgery for any eligible patient. But more than just offering options that include PRK, LASIK, PRESBYOND® Laser Blended Vision and SMILE® Lenticule Extraction, ZEISS delivers outstanding clinical application support and comprehensive business consulting that can help surgeons and staff continually succeed. Take advantage of a variety of premier solutions from the global market leader1 in laser vision correction.

Leading the way

Extend your LVC portfolio with the global market leader1.

Pioneering innovation
With more than 30 years of experience in Laser Vision Correction and more than 3.5 million treated eyes with SMILE, ZEISS has shaped the refractive surgery field.

Global support
Trained ZEISS specialists deliver application support around the world, including in-depth onboarding, continuous assistance and ZEISS Practice Development Consulting to evaluate the patient experience in your clinic.

Trusted network
Over 2,000 surgeons from more than 80 countries rely on the ZEISS LVC portfolio for improved vision – some of them for their own eyes and the vision of their loved ones.

Dr. Robert Morris, Consultant Ophthalmic Surgeon Optegra Eye Hospital, London, UK

I was a longstanding myope and was thinking about refractive surgery to deal with my presbyopia and contact lens intolerance, and underwent very successful laser eye surgery with PRESBYOND four years ago.2

See what sets us apart.

ZEISS Corneal Refractive Workflow

Learn how ZEISS can help you streamline your workflow and enhance outcomes with the right solution for any eligible patient.

Unable to load form (multistep).
  • 1 2020 Refractive Surgery Market Report – estimated total revenue.
  • 2 Statement from November, 2020, Case of the Month, Ophthalmology Times Europe, Vol.16, No.9